Abstract
The sharing of legacy preclinical safety data among pharmaceutical companies and its integration with other information sources offers unprecedented opportunities to improve the early assessment of drug safety. Here, we discuss the experience of the eTOX project, which was established through the Innovative Medicines Initiative to explore this possibility.
| Original language | English |
|---|---|
| Pages (from-to) | 811-812 |
| Number of pages | 2 |
| Journal | Nature Reviews Drug Discovery |
| Volume | 16 |
| Issue number | 12 |
| Early online date | 13 Oct 2017 |
| DOIs |
|
| Publication status | Published - Dec 2017 |
Funding
| Funders | Funder number |
|---|---|
| Horizon 2020 Framework Programme | 777365 |
| Horizon 2020 Framework Programme |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Drug Evaluation, Preclinical
- Drug Industry
- Drug-Related Side Effects and Adverse Reactions
- Humans
- Information Dissemination
- Journal Article
- Risk Assessment
Fingerprint
Dive into the research topics of 'Legacy data sharing to improve drug safety assessment: the eTOX project'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver